跳至主要内容
临床试验/NCT01248429
NCT01248429已完成不适用

National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)

Centre Oscar Lambret27 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2010年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
154
试验地点
27
主要终点
To evaluate the prevalence of the CPK increase

研究概览

简要总结

This study describes the elevation of CPK in patient treated for solid tumors by TKI

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
  • Patient examined AND with a routine blood test planned
  • Patient informed of procedure for the study who was not opposed to it

排除标准

  • Patient treated for malignant hemopathy
  • Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
  • Patients with no routine blood laboratory tests planned

研究组 & 干预措施

Patient treated by TKI

Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week

干预措施: CPK dosage (Biological)

Patient treated by TKI

Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week

干预措施: Clinical exam (Other)

结局指标

主要结局

To evaluate the prevalence of the CPK increase

时间窗: Within 3 days after a clinical exam

Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value \> USL

次要结局

  • Correlation myalgia/CPK increase(During the clinical exam)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (27)

Loading locations...

相似试验